Compare · GLP-1 agonist
Ecnoglutide vs Mazdutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Ecnoglutide | Mazdutide | |
|---|---|---|
| Evidence | Preliminary human | Preliminary human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A long-acting, cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and weight management, with genuine peer-reviewed Phase 3 data that is still confined to Chinese populations and not FDA-approved. | A GLP-1/glucagon dual agonist approved in China for weight loss and diabetes, with genuine RCT evidence that is still sponsor-funded and single-country. |
| Full profile → | Full profile → |
Ecnoglutide
Ecnoglutide (development code XW003) is an injectable drug for type 2 diabetes and weight loss that belongs to the same broad GLP-1 receptor agonist family as semaglutide. It stands out for two reasons: its developer engineered it to be "cAMP-biased," a real and characterized pharmacological…
Mazdutide
Mazdutide is an injectable drug for weight loss and type 2 diabetes that activates two metabolic hormone receptors at once. Unlike most of the attention-grabbing GLP-1 compounds, it is not stuck at the press-release stage: it has a published Phase 3 trial in a major journal and is actually approved…